 | ||||||||||
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
|
 Viral Genetics Announces Licensing Deal With University of Colorado and V-Clip Pharmaceuticals, Inc. |
| ||
Viral Genetics is developing immune-based therapies for the treatment of HIV/AIDS and other infectious, autoimmune, and immunological deficiency disorders. The Company’s primary product candidate is VGV-1, an investigational therapy for the treatment of HIV/AIDS that has demonstrated an antiviral effect in clinical trials with an apparent immunological mechanism of action. VGV-1 is a suspension of Thymus Nuclear Protein in adjuvant. Viral Genetics licensed technology developed by Dr. Karen Newell at the University of Colorado. The technology may explain the mechanism of action of TNP as well as identify its active components. The Company is now performing studies to confirm this as it would likely allow optimization of the Company’s VGV-1 investigational drug for clinical study.
|
|
|
|
Home | About Us | Our Team | Scientific Advisory Board | Discovery Vision | Immune-Based Therapies | TNP | Development | VGV-1 History | Product Timeline | Clinical Trials Press Releases | Media Kits | Media Inquiries | News Subscription Service Investor Contacts | Email Alerts | Fact Sheet | Contact Us | SEC Filings Glossary | Stock Information | Corporate Governance & Board of Directors University of Colorado License | Careers |
|
|
 |
|
|
